KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.96

A Subgroup Analysis of Perioperative Pembrolizumab in Clinical Stage II Non-Small-Cell Lung Cancer from the Randomized KEYNOTE-671 Study.

Masahiro Tsuboi, Heather Wakelee, Marina C Garassino, Shugeng Gao, Alexander Luft, Ke-Neng Chen, Jonathan D Spicer, Yuming Zhu, Hisashi Saji, Morihito Okada, Tõnu Vanakesa, Haiquan Chen, Guofang Zhao, Norihiko Ikeda, David R Jones, Benny Weksler, Chien-Sheng Huang, Erin Jensen, Steven M Keller, Ayman Samkari, Moishe Liberman

Eur J Cardiothorac Surg 68(3) ezag028

PMID41875364
PMCIDPMC13020334
DOI10.1093/ejcts/ezag028
发表日期2026-03-24
入排依据:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
摘要

摘要

OBJECTIVES: Perioperative pembrolizumab plus neoadjuvant chemotherapy significantly improved outcomes versus neoadjuvant chemotherapy alone in early-stage, resectable, non-small-cell lung cancer (NSCLC) in the phase 3 KEYNOTE-671 study. We report outcomes in participants with baseline clinical stage II disease. METHODS: Participants with untreated, resectable, stage II-IIIB (N2) NSCLC were randomized 1:1 to receive pembrolizumab 200 mg or placebo every 3 weeks plus chemotherapy for 4 cycles, followed by surgery and adjuvant pembrolizumab or placebo for 13 cycles (∼9 months). Exploratory analyses were performed in participants with clinical stage II disease. RESULTS: Of 797 randomized participants, 239 had stage II disease (pembrolizumab plus chemotherapy, n = 118; chemotherapy only, n = 121). Median study follow-up at data cutoff (August 19, 2024) was 49.9 (range, 32.2-75.3) months. Among participants who underwent surgery, 94/99 (94.9%) had R0 resections in the pembrolizumab arm and 89/103 (86.4%) in the neoadjuvant chemotherapy only arm. Event-free survival (hazard ratio [HR], 0.50; 95% CI, 0.34-0.74), overall survival (HR, 0.69; 95% CI, 0.43-1.11), major pathological response (difference, 25.7%; 95% CI, 15.3-35.9), and pathological complete response (difference, 21.3%; 95% CI, 13.2-30.2) were improved in the pembrolizumab arm. Grade 3-4 treatment-related adverse events (AEs) occurred in 50.0% of participants treated with pembrolizumab plus chemotherapy and 40.5% with chemotherapy; no treatment-related AEs led to death. CONCLUSIONS: In participants with stage II NSCLC, perioperative pembrolizumab improved efficacy outcomes with manageable safety versus neoadjuvant chemotherapy alone, consistent with the overall KEYNOTE-671 population. These results support the use of this regimen in patients with stage II disease. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03425643, registered/first posted on February 7, 2018 (https://www.clinicaltrials.gov/study/NCT03425643).

KM 提取结果

2 个 Figure · 6 个 KM 面板

进入结果中心
KM Figure3 个面板

Figure 2

Figure 2. Event-free survival in participants with clinical stage (A) II, (B) IIA, and (C) IIB NSCLC. Abbreviations: Chemo, chemotherapy; EFS, event-free survival; HR, hazard ratio; NR, not reached; NSCLC, non-small-cell lung cancer; Pembro, pembrolizumab.

A

Event-Free Survival

Figure 2 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

Event-Free Survival

Figure 2 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
C

Event-Free Survival

Figure 2 · Panel C

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel C 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure3 个面板

Figure 3

Figure 3. Overall survival in participants with clinical stage (A) II, (B) IIA, and (C) IIB NSCLC. Abbreviations: Chemo, chemotherapy; HR, hazard ratio; NR, not reached; NSCLC, non-small-cell lung cancer; OS, overall survival; Pembro, pembrolizumab.

A

Overall Survival

Figure 3 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:extreme upward reversal
查看结果
B

Overall Survival

Figure 3 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
C

Overall Survival

Figure 3 · Panel C

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel C 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:extreme upward reversal
查看结果
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

captionless-figureGraphical abstract
非 KM Figure
Figure 1Figure 1. Treatment Disposition. Percentages are based on the number of participants who started neoadjuvant therapy. a Includes clinical progression, local progression preventing surgery, and radiographic progression. b Includes 1 participant who received in-study radiotherapy instead of surgery. c Includes 3 participants who received in-study radiotherapy instead of surgery. Abbreviation: AE, adverse event.
非 KM Figure
Figure 4Figure 4. (A) MPR and (B) pCR in participants with clinical stage II, IIA, and IIB NSCLC. Abbreviations: Chemo, chemotherapy; MPR, major pathologic response; NSCLC, non-small-cell lung cancer; pCR, pathologic complete response; Pembro, pembrolizumab.
非 KM Figure